Manipal Hospitals to Acquire Sahyadri for ₹6,400 Cr in Major Healthcare Deal

New Delhi — In a major development in India’s private healthcare landscape, Manipal Hospitals has sought approval from the Competition Commission of India (CCI) to acquire Sahyadri Hospitals, a leading Western India-based hospital chain, for a reported ₹6,400 crore.

This strategic move is expected to bolster Manipal’s footprint in Maharashtra and consolidate its position as one of the top three hospital networks in the country by bed capacity and revenue.

🏥 Sahyadri’s Presence:

Sahyadri Hospitals operates nine multi-speciality hospitals across cities like Pune, Nashik, and Karad, with a total bed strength of over 900 beds. The chain is known for its strong clinical specialties in oncology, neurology, cardiology, and organ transplants.

💼 Strategic Push by Manipal:

Manipal Hospitals, backed by global investment firm TPG Capital, has been actively expanding. The group previously acquired Columbia Asia and Vikram Hospital, building one of India’s largest integrated health networks.

This latest deal signals continued consolidation in India’s private healthcare market, driven by the rising demand for quality tertiary care, operational synergies, and access to underserved regional hubs.

🔍 What Comes Next:

The acquisition plan now awaits CCI’s approval, which is a mandatory regulatory step to ensure compliance with India’s antitrust laws. If cleared, the integration is likely to enhance patient access to Manipal’s standardised protocols, advanced medical tech, and streamlined care delivery across Western India.

Related Posts

NHS backs delayed‑release treatment for cystinosis

Decision expands options for eligible patients NHS England has recommended delayed‑release mercaptamine bitartrate for routine commissioning for eligible patients aged one year and above with nephropathic cystinosis. The decision provides…

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Mumbai/Pune: In a major regulatory enforcement action aimed at safeguarding public health, the Maharashtra Food and Drug Administration (FDA) has permanently cancelled the Ayurvedic drug manufacturing licence of Pune-based M/s Inducare Pharma…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

NHS backs delayed‑release treatment for cystinosis

NHS backs delayed‑release treatment for cystinosis

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

AmeriHealth Home Healthcare Celebrates 5 Years of Compassionate Care

AmeriHealth Home Healthcare Celebrates 5 Years of Compassionate Care